Soni Shaikh

Soni Shaikh

Auto-generated profile, based on publicly available information

Soni Shaikh

University of Kalyani

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
PKPulak Kar
Pulak Kar
KSKrishna Samanta
Krishna Samanta
SSSoni Shaikh
Soni Shaikh
ACAnimesh Chowdhury
Animesh Chowdhury
TCTapati Chakraborti
Tapati Chakraborti
SCSajal Chakraborti
Sajal Chakraborti

31 January 2018 in Cancer Research
Verified
Journal Article
Open access
PDF file
MSMarta C. Sallán
Marta C. Sallán
AVAnna Visa
Anna Visa
SSSoni Shaikh
Soni Shaikh
MNMireia Nàger
Mireia Nàger
JHJudit Herreros
Judit Herreros
CCCarles Cantí
Carles Cantí
In the past decade, T-type Ca2+ channels (TTCC) have been unveiled as key regulators of cancer cell biology and thus have been proposed as chemotherapeutic targets. Indeed, in vitro and in vivo studies indicate that TTCC pharmacologic blockers have a negative impact on the viability of cancer cells and reduce tumor size, respectively. Consequently mibefradil, a TTCC blocker approved in 1997 as an antihypertensive agent but withdrawn in 1998 because of drug–drug interactions, was granted 10 years later the orphan drug status by the FDA to investigate its efficacy against brain, ovary, and pancreatic cancer. However, the existence of different channel isoforms with distinct physiologic roles, together with the lack of selective pharmacologic agents, has hindered a conclusive chemotherapeutic evaluation. Here, we review the available evidence on TTCC expression, value as prognostic markers, and effectiveness of their pharmacologic blockade on cancer cells in vitro and in preclinical models. We additionally summarize the status of clinical trials using mibefradil against glioblastoma multiforme. Finally, we discuss the future perspectives and the importance of further development of multidisciplinary research efforts on the consideration of TTCCs as biomarkers or targetable molecules in cancer. Cancer Res; 78(3); 1–7. ©2018 AACR.

1 July 2009 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
SCSajal Chakraborti
Sajal Chakraborti
ACAnimesh Chowdhury
Animesh Chowdhury
PKPulak Kar
Pulak Kar
PDPartha Das
Partha Das
SSSoni Shaikh
Soni Shaikh
TCTapati Chakraborti
Tapati Chakraborti

1 July 2012 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
SCSajal Chakraborti
Sajal Chakraborti
SRSoumitra Roy
Soumitra Roy
AMAmritlal Mandal
Amritlal Mandal
KDKuntal Dey
Kuntal Dey
ACAnimesh Chowdhury
Animesh Chowdhury
TCTapati Chakraborti
Tapati Chakraborti

1 July 2019 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
AVAnna Visa
Anna Visa
SSSoni Shaikh
Soni Shaikh
LALía Alza
Lía Alza
JHJudit Herreros
Judit Herreros
CCCarles Cantí
Carles Cantí

15 October 2019 in Current Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
SSSoni Shaikh
Soni Shaikh
SNSuman KUMAR Nandy
Suman KUMAR Nandy
CCCarles Cantí
Carles Cantí
SLSergio Lavandero
Sergio Lavandero
Objective: Bafilomycin-A1 and ML9 are lysosomotropic agents, irrespective of cell types. However, the mechanisms of lysosome targeting either bafilomycin-A1 or ML9 are unclear.Methods: The present research has been carried out by different molecular and biochemical analyses like western blot, confocal imaging and FACS studies, as well as molecular docking.Results: Our data shows that pre-incubation of neonatal cardiomyocytes with ML9 for 4h induced cell death, whereas a longer period of time (24h) with bafilomycin-A1 was required to induce an equivalent effect. Neither changes in ROS nor ATP production is associated with such death mechanisms. Flow cytometry, LC3-II expression levels, and LC3-GFP puncta formation revealed a similar lysosomotropic effect for both compounds. We used a molecular docking approach, that predicts a stronger inhibitory activity against V-ATPase-C1 and C2 domains for bafilomycin-A1 in comparison to ML9.Conclusion: Bafilomycin-A1 and ML9 are lysosomotropic agents, involved in cell death events. But such death events are not associated with ATP and ROS production. Furthermore, both the drugs target lysosomes through different mechanisms. For the latter, cell death is likely due to lysosomal membrane permeabilization and release of lysosomal proteases into the cytosol.